Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition
9 May 2026 – 14 May 2026 · Cape Town, South Africa
301-02-003 ISMRM Abstract

Improving MRI Accuracy After Immunotherapy-based Total Neoadjuvant Therapy in Rectal Cancer: Role of a DWI-Adjusted Scoring S

Primary: Analysis Methods - Classification and Prediction
Secondary: Body - Digestive
301-02-003 · Advances in Rectum and Pelvis MRI · Monday, 11 May, 8:20 AM–10:10 AM · Hall 1A
Accepted
Dandan Li1,2, Tong Tong 1, Tingdan Hu1, Yanfen Cui3,4
1Fudan University Shanghai Cancer Center, Shanghai, China
2Department of Radiology, Fudan University Shanghai Cancer Center, Shanghai, China
3Shanxi Province Cancer Hospital/ Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan, China
4Department of Radiology, Shanxi Province Cancer Hospital/ Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan, China
Presenting Author: Tong Tong

Synopsis

Motivation:
Goals:
Approach:
Results:
Full abstract & presentation

The full text, figures, and any recorded presentation for this abstract are not shown here. Log in if you are a member or registered attendee with access.

Full abstracts, figures, and presentations for Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition are available to registered attendees. This content becomes freely available to the public roughly two years after the meeting.

To request or purchase access, contact the ISMRM Central Office at info@ismrm.org.

Log in

References

1. 1.Overman MJ, McDermott R, Leach JL, et al (2017) Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol 18:1182–1191. https://doi.org/10.1016/S1470-2045(17)30422-9 [doi]
2. 2.Asaoka Y, Ijichi H, Koike K (2015) PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med 373:1979. https://doi.org/10.1056/NEJMc1510353 [doi]
3. 3.Demaria S, Coleman CN, Formenti SC (2016) Radiotherapy: Changing the Game in Immunotherapy. Trends Cancer 2:286–294. https://doi.org/10.1016/j.trecan.2016.05.002 [doi]
4. 4.Lim JYH, Gerber SA, Murphy SP, Lord EM (2014) Type I interferons induced by radiation therapy mediate recruitment and effector function of CD8(+) T cells. Cancer Immunol Immunother 63:259–271. https://doi.org/10.1007/s00262-013-1506-7 [doi]
5. 5.Xia F, Wang Y, Wang H, et al (2024) Randomized Phase II Trial of Immunotherapy-Based Total Neoadjuvant Therapy for Proficient Mismatch Repair or Microsatellite Stable Locally Advanced Rectal Cancer (TORCH). JCO 42:3308–3318. https://doi.org/10.1200/JCO.23.02261 [doi]
6. 6.Zhai M, Lin Z, Wang H, et al (2023) Can rectal MRI and endorectal ultrasound accurately predict the complete response to neoadjuvant immunotherapy for rectal cancer? Gastroenterology Report 12:goae027. https://doi.org/10.1093/gastro/goae027 [doi]
7. 7.Shen Y, Gong X, He Y, et al (2024) MRI Tumor Regression Response to Neoadjuvant Chemotherapy Alone without Radiation for Rectal Adenocarcinoma. Radiology 312:e232908. https://doi.org/10.1148/radiol.232908 [doi]
8. 8.Hall WA, Li J, You YN, et al. (2024) Prospective correlation of magnetic resonance tumor regression grade with pathologic outcomes in total neoadjuvant therapy for rectal adenocarcinoma. J Clin Oncol 42: JCO.22.02525. https://doi.org/10.1200/JCO.22.02525 [doi]
9. 9.Colle R, Radzik A, Cohen R, et al. (2021) Pseudoprogression in patients treated with immune checkpoint inhibitors for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer. Eur J Cancer 144:9–16. https://doi.org/10.1016/j.ejca.2020.11.036 [doi]
10. 10.Zhao P, Li L, Jiang X, et al. (2019) Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy. J Hematol Oncol 12:54. https://doi.org/10.1186/s13045-019-0738-x [doi]
11. 11.Diaz LA Jr, Shiu KK, Kim TW, et al. (2022) Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study. Lancet Oncol 23:659–670. https://doi.org/10.1016/S1470-2045(22)00197-8 [doi]

Cite this abstract

http://echo.ismrm.org/p/ISMRM2026/301-02-003